A NEW bath treatment for sea lice has proven 100 per cent effective in commercial field trials in Norway, said its manufacturer.
The treatment, called Ectosan, was developed by Benchmark, which described the product as a ‘breakthrough’ in addressing the salmon farming industry’s sea lice challenge.
Furthermore, the invention is hailed as environmentally friendly as it is administered through a purification system, CleanTreat, which removes any detectable traces of medicine from treatment water before it is discharged into the ocean.
The system, which Benchmark claims is the first of its kind to be used in aquaculture, has applications beyond the company’s sea lice treatment. The company is now exploring these applications and routes to market for the technology.
Benchmark believes Ectosan has annual sales potential of £40-50 million, and it will continue field trials in key markets through 2018 and 2019 as part of the regulatory process.
Malcolm Pye, CEO of Benchmark, said: ‘This is major breakthrough for Benchmark and the salmon industry. The combination of our next generation sea lice treatment, together with CleanTreat, represents a transformational change in the battle against one of the industry’s greatest challenges, and a big step towards a future where no medicinal residues are discharged directly into the oceans.
‘Given its significance to the industry and interest expressed by our customers, we expect to see substantial demand for the treatment and look forward to providing the treatment more widely upon regulatory approval.’
Picture: Benchmark CEO Malcolm Pye